InvestorsHub Logo
Followers 1
Posts 206
Boards Moderated 0
Alias Born 04/06/2013

Re: lux1 post# 12337

Thursday, 12/14/2017 1:26:47 PM

Thursday, December 14, 2017 1:26:47 PM

Post# of 43784
At Clinicaltrial they don't say 10% of OS improvement but only the more usual P-Value between the 2 group less than 0.05.
Not a little difference.

Primary Outcome Measures:
Overall Survival (OS) in LI + CIZ + SOC vs. SOC [ Time Frame: 3 year ]
OS will be assessed using Kaplan-Meier life-table and compared using a logrank test and confirmed further with tumor stage location and geographic stratified log rank tests. The unstratified logrank test constitutes the primary analysis. A two-sided p-value of 0.05 or less will be considered statistically significant for comparing the two groups. Interim analyses will be performed throughout the study to assess safety, sample size and futility.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News